UNH 10-Q Quarterly Report March 31, 2025

UNITEDHEALTH GROUP INC

10-Qs and 10-Ks

10-Q	Quarter ended March 31, 2025
10-K	Fiscal year ended Dec. 31, 2024
10-Q	Quarter ended Sept. 30, 2024
10-Q	Quarter ended June 30, 2024
10-Q	Quarter ended March 31, 2024
10-K	Fiscal year ended Dec. 31, 2023
10-Q	Quarter ended Sept. 30, 2023
10-Q	Quarter ended June 30, 2023
10-Q	Quarter ended March 31, 2023
10-K	Fiscal year ended Dec. 31, 2022
10-Q	Quarter ended Sept. 30, 2022
10-Q	Quarter ended June 30, 2022
10-Q	Quarter ended March 31, 2022
10-K	Fiscal year ended Dec. 31, 2021
10-Q	Quarter ended Sept. 30, 2021
10-Q	Quarter ended June 30, 2021
10-Q	Quarter ended March 31, 2021
10-K	Fiscal year ended Dec. 31, 2020
10-Q	Quarter ended Sept. 30, 2020
10-Q	Quarter ended June 30, 2020
10-Q	Quarter ended March 31, 2020
10-K	Fiscal year ended Dec. 31, 2019
10-Q	Quarter ended Sept. 30, 2019
10-Q	Quarter ended June 30, 2019
10-Q	Quarter ended March 31, 2019
10-K	Fiscal year ended Dec. 31, 2018
10-Q	Quarter ended Sept. 30, 2018
10-Q	Quarter ended June 30, 2018
10-Q	Quarter ended March 31, 2018
10-K	Fiscal year ended Dec. 31, 2017
10-Q	Quarter ended Sept. 30, 2017
10-Q	Quarter ended June 30, 2017
10-Q	Quarter ended March 31, 2017
10-K	Fiscal year ended Dec. 31, 2016
10-Q	Quarter ended Sept. 30, 2016
10-Q	Quarter ended June 30, 2016
10-Q	Quarter ended March 31, 2016
10-K	Fiscal year ended Dec. 31, 2015
10-Q	Quarter ended Sept. 30, 2015
10-Q	Quarter ended June 30, 2015
10-Q	Quarter ended March 31, 2015
10-K	Fiscal year ended Dec. 31, 2014
10-Q	Quarter ended Sept. 30, 2014
10-Q	Quarter ended June 30, 2014
10-Q	Quarter ended March 31, 2014
10-K	Fiscal year ended Dec. 31, 2013
10-Q	Quarter ended Sept. 30, 2013
10-Q	Quarter ended June 30, 2013
10-Q	Quarter ended March 31, 2013
10-K	Fiscal year ended Dec. 31, 2012
10-Q	Quarter ended Sept. 30, 2012
10-Q	Quarter ended June 30, 2012
10-Q	Quarter ended March 31, 2012
10-K	Fiscal year ended Dec. 31, 2011
10-Q	Quarter ended Sept. 30, 2011
10-Q	Quarter ended June 30, 2011
10-Q	Quarter ended March 31, 2011
10-K	Fiscal year ended Dec. 31, 2010
10-Q	Quarter ended Sept. 30, 2010
10-Q	Quarter ended June 30, 2010
10-Q	Quarter ended March 31, 2010
10-K	Fiscal year ended Dec. 31, 2009

PROXIES

DEF 14A	Filed on April 21, 2025
DEF 14A	Filed on April 22, 2024
DEF 14A	Filed on April 21, 2023
DEF 14A	Filed on April 22, 2022
DEF 14A	Filed on April 26, 2021
DEF 14A	Filed on April 17, 2020
DEF 14A	Filed on April 19, 2019
DEF 14A	Filed on April 20, 2018
DEF 14A	Filed on April 21, 2017
DEF 14A	Filed on April 22, 2016
DEF 14A	Filed on April 22, 2015
DEF 14A	Filed on April 23, 2014
DEF 14A	Filed on April 24, 2013
DEF 14A	Filed on April 25, 2012
DEF 14A	Filed on April 13, 2011
DEF 14A	Filed on April 14, 2010

unh-20250331

false 2025 Q1 0000731766 12/31 50 xbrli:shares iso4217:USD iso4217:USD xbrli:shares utr:Rate xbrli:pure unh:reportableSegments 0000731766 2025-01-01 2025-03-31 0000731766 2025-04-30 0000731766 2025-03-31 0000731766 2024-12-31 0000731766 2024-01-01 2024-03-31 0000731766 us-gaap:ProductMember 2025-01-01 2025-03-31 0000731766 us-gaap:ProductMember 2024-01-01 2024-03-31 0000731766 us-gaap:ServiceMember 2025-01-01 2025-03-31 0000731766 us-gaap:ServiceMember 2024-01-01 2024-03-31 0000731766 us-gaap:CommonStockMember 2024-12-31 0000731766 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000731766 us-gaap:RetainedEarningsMember 2024-12-31 0000731766 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-12-31 0000731766 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-31 0000731766 us-gaap:NoncontrollingInterestMember 2024-12-31 0000731766 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000731766 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0000731766 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2025-01-01 2025-03-31 0000731766 us-gaap:AccumulatedTranslationAdjustmentMember 2025-01-01 2025-03-31 0000731766 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000731766 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000731766 us-gaap:CommonStockMember 2025-03-31 0000731766 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000731766 us-gaap:RetainedEarningsMember 2025-03-31 0000731766 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2025-03-31 0000731766 us-gaap:AccumulatedTranslationAdjustmentMember 2025-03-31 0000731766 us-gaap:NoncontrollingInterestMember 2025-03-31 0000731766 us-gaap:CommonStockMember 2023-12-31 0000731766 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000731766 us-gaap:RetainedEarningsMember 2023-12-31 0000731766 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0000731766 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000731766 us-gaap:NoncontrollingInterestMember 2023-12-31 0000731766 2023-12-31 0000731766 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000731766 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0000731766 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-01 2024-03-31 0000731766 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-03-31 0000731766 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000731766 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000731766 us-gaap:CommonStockMember 2024-03-31 0000731766 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000731766 us-gaap:RetainedEarningsMember 2024-03-31 0000731766 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-03-31 0000731766 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31 0000731766 us-gaap:NoncontrollingInterestMember 2024-03-31 0000731766 2024-03-31 0000731766 unh:ProductsAndServicesMember 2025-03-31 0000731766 unh:ProductsAndServicesMember 2024-12-31 0000731766

2025-04-01

2025-03-31 0000731766 us-gaap:USTreasuryAndGovernmentMember 2025-03-31 0000731766 us-gaap:USStatesAndPoliticalSubdivisionsMember 2025-03-31 0000731766 us-gaap:CorporateDebtSecuritiesMember 2025-03-31 0000731766 us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2025-03-31 0000731766 us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember 2025-03-31 0000731766 us-gaap:USTreasuryAndGovernmentMember 2024-12-31 0000731766 us-gaap:USStatesAndPoliticalSubdivisionsMember 2024-12-31 0000731766 us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000731766 us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2024-12-31 0000731766 us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember 2024-12-31 0000731766 us-gaap:DebtSecuritiesMember 2025-03-31 0000731766 us-gaap:DebtSecuritiesMember 2024-12-31 0000731766 us-gaap:FairValueInputsLevel1Member 2025-03-31 0000731766 us-gaap:FairValueInputsLevel2Member 2025-03-31 0000731766 us-gaap:FairValueInputsLevel3Member 2025-03-31 0000731766 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member 2025-03-31 0000731766 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member 2025-03-31 0000731766 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member 2025-03-31 0000731766 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel1Member 2025-03-31 0000731766 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel2Member 2025-03-31 0000731766 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel3Member 2025-03-31 0000731766 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2025-03-31 0000731766 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2025-03-31 0000731766 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2025-03-31 0000731766 us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember us-gaap:FairValueInputsLevel1Member 2025-03-31 0000731766 us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember us-gaap:FairValueInputsLevel2Member 2025-03-31 0000731766 us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember us-gaap:FairValueInputsLevel3Member 2025-03-31 0000731766 us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember us-gaap:FairValueInputsLevel1Member 2025-03-31 0000731766 us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember us-gaap:FairValueInputsLevel2Member 2025-03-31 0000731766 us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember us-gaap:FairValueInputsLevel3Member 2025-03-31 0000731766 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2025-03-31 0000731766 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2025-03-31 0000731766 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2025-03-31 0000731766 us-gaap:FairValueInputsLevel1Member 2024-12-31 0000731766 us-gaap:FairValueInputsLevel2Member 2024-12-31 0000731766 us-gaap:FairValueInputsLevel3Member 2024-12-31 0000731766 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000731766 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000731766 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0000731766 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000731766 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000731766 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0000731766 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000731766 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000731766 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0000731766 us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000731766 us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000731766 us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0000731766 us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000731766 us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000731766 us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0000731766 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000731766 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000731766 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0000731766 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FairValueInputsLevel1Member 2025-03-31 0000731766 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FairValueInputsLevel2Member 2025-03-31 0000731766 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FairValueInputsLevel3Member 2025-03-31 0000731766 us-gaap:FairValueMeasurementsNonrecurringMember 2025-03-31 0000731766 us-gaap:LongTermDebtMember 2025-03-31 0000731766 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000731766 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000731766 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0000731766 us-gaap:FairValueMeasurementsNonrecurringMember 2024-12-31 0000731766 us-gaap:LongTermDebtMember 2024-12-31 0000731766 us-gaap:CommercialPaperMember 2025-03-31 0000731766 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:ExternalCustomersMember unh:UnitedhealthcareMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:ExternalCustomersMember unh:OptumHealthMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:ExternalCustomersMember unh:OptumInsightMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:ExternalCustomersMember unh:OptumRxMember 2025-01-01 2025-03-31 0000731766 us-gaap:IntersegmentEliminationMember unh:ExternalCustomersMember 2025-01-01 2025-03-31 0000731766 unh:ExternalCustomersMember unh:TotalOptumMember 2025-01-01 2025-03-31 0000731766 us-gaap:CorporateNonSegmentMember unh:ExternalCustomersMember 2025-01-01 2025-03-31 0000731766 unh:ExternalCustomersMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember us-gaap:ProductMember unh:ExternalCustomersMember unh:UnitedhealthcareMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember us-gaap:ProductMember unh:ExternalCustomersMember unh:OptumHealthMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember us-gaap:ProductMember unh:ExternalCustomersMember unh:OptumInsightMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember us-gaap:ProductMember unh:ExternalCustomersMember unh:OptumRxMember 2025-01-01 2025-03-31 0000731766 us-gaap:IntersegmentEliminationMember us-gaap:ProductMember unh:ExternalCustomersMember 2025-01-01 2025-03-31 0000731766 us-gaap:ProductMember unh:ExternalCustomersMember unh:TotalOptumMember 2025-01-01 2025-03-31 0000731766 us-gaap:CorporateNonSegmentMember us-gaap:ProductMember unh:ExternalCustomersMember 2025-01-01 2025-03-31 0000731766 us-gaap:ProductMember unh:ExternalCustomersMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember unh:ExternalCustomersMember unh:UnitedhealthcareMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember unh:ExternalCustomersMember unh:OptumHealthMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember unh:ExternalCustomersMember unh:OptumInsightMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember unh:ExternalCustomersMember unh:OptumRxMember 2025-01-01 2025-03-31 0000731766 us-gaap:IntersegmentEliminationMember us-gaap:ServiceMember unh:ExternalCustomersMember 2025-01-01 2025-03-31 0000731766 us-gaap:ServiceMember unh:ExternalCustomersMember unh:TotalOptumMember 2025-01-01 2025-03-31 0000731766 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember unh:ExternalCustomersMember 2025-01-01 2025-03-31 0000731766 us-gaap:ServiceMember unh:ExternalCustomersMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:IntersegmentMember unh:UnitedhealthcareMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:IntersegmentMember unh:OptumHealthMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:IntersegmentMember unh:OptumInsightMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:IntersegmentMember unh:OptumRxMember 2025-01-01 2025-03-31 0000731766 us-gaap:IntersegmentEliminationMember unh:IntersegmentMember 2025-01-01 2025-03-31 0000731766 unh:IntersegmentMember unh:TotalOptumMember 2025-01-01 2025-03-31 0000731766 us-gaap:CorporateNonSegmentMember unh:IntersegmentMember 2025-01-01 2025-03-31 0000731766 unh:IntersegmentMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:UnitedhealthcareMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:OptumHealthMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:OptumInsightMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:OptumRxMember 2025-01-01 2025-03-31 0000731766 us-gaap:IntersegmentEliminationMember 2025-01-01 2025-03-31 0000731766 unh:TotalOptumMember 2025-01-01 2025-03-31 0000731766 us-gaap:CorporateNonSegmentMember 2025-01-01 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:UnitedhealthcareMember 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:OptumHealthMember 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:OptumInsightMember 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:OptumRxMember 2025-03-31 0000731766 us-gaap:IntersegmentEliminationMember 2025-03-31 0000731766 unh:TotalOptumMember 2025-03-31 0000731766 us-gaap:CorporateNonSegmentMember 2025-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:ExternalCustomersMember unh:UnitedhealthcareMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:ExternalCustomersMember unh:OptumHealthMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:ExternalCustomersMember unh:OptumInsightMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:ExternalCustomersMember unh:OptumRxMember 2024-01-01 2024-03-31 0000731766 us-gaap:IntersegmentEliminationMember unh:ExternalCustomersMember 2024-01-01 2024-03-31 0000731766 unh:ExternalCustomersMember unh:TotalOptumMember 2024-01-01 2024-03-31 0000731766 us-gaap:CorporateNonSegmentMember unh:ExternalCustomersMember 2024-01-01 2024-03-31 0000731766 unh:ExternalCustomersMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember us-gaap:ProductMember unh:ExternalCustomersMember unh:UnitedhealthcareMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember us-gaap:ProductMember unh:ExternalCustomersMember unh:OptumHealthMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember us-gaap:ProductMember unh:ExternalCustomersMember unh:OptumInsightMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember us-gaap:ProductMember unh:ExternalCustomersMember unh:OptumRxMember 2024-01-01 2024-03-31 0000731766 us-gaap:IntersegmentEliminationMember us-gaap:ProductMember unh:ExternalCustomersMember 2024-01-01 2024-03-31 0000731766 us-gaap:ProductMember unh:ExternalCustomersMember unh:TotalOptumMember 2024-01-01 2024-03-31 0000731766 us-gaap:CorporateNonSegmentMember us-gaap:ProductMember unh:ExternalCustomersMember 2024-01-01 2024-03-31 0000731766 us-gaap:ProductMember unh:ExternalCustomersMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember unh:ExternalCustomersMember unh:UnitedhealthcareMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember unh:ExternalCustomersMember unh:OptumHealthMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember unh:ExternalCustomersMember unh:OptumInsightMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember unh:ExternalCustomersMember unh:OptumRxMember 2024-01-01 2024-03-31 0000731766 us-gaap:IntersegmentEliminationMember us-gaap:ServiceMember unh:ExternalCustomersMember 2024-01-01 2024-03-31 0000731766 us-gaap:ServiceMember unh:ExternalCustomersMember unh:TotalOptumMember 2024-01-01 2024-03-31 0000731766 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember unh:ExternalCustomersMember 2024-01-01 2024-03-31 0000731766 us-gaap:ServiceMember unh:ExternalCustomersMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:IntersegmentMember unh:UnitedhealthcareMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:IntersegmentMember unh:OptumHealthMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:IntersegmentMember unh:OptumInsightMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:IntersegmentMember unh:OptumRxMember 2024-01-01 2024-03-31 0000731766 us-gaap:IntersegmentEliminationMember unh:IntersegmentMember 2024-01-01 2024-03-31 0000731766 unh:IntersegmentMember unh:TotalOptumMember 2024-01-01 2024-03-31 0000731766 us-gaap:CorporateNonSegmentMember unh:IntersegmentMember 2024-01-01 2024-03-31 0000731766 unh:IntersegmentMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:UnitedhealthcareMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:OptumHealthMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:OptumInsightMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:OptumRxMember 2024-01-01 2024-03-31 0000731766 us-gaap:IntersegmentEliminationMember 2024-01-01 2024-03-31 0000731766 unh:TotalOptumMember 2024-01-01 2024-03-31 0000731766 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:TotalOptumMember 2024-01-01 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:UnitedhealthcareMember 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:OptumHealthMember 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:OptumInsightMember 2024-03-31 0000731766 us-gaap:OperatingSegmentsMember unh:OptumRxMember 2024-03-31 0000731766 us-gaap:IntersegmentEliminationMember 2024-03-31 0000731766 unh:TotalOptumMember 2024-03-31 0000731766 us-gaap:CorporateNonSegmentMember 2024-03-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________________________________________________

FORM 10-Q

__________________________________________________________


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2025


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission File Number: 1-10864

__________________________________________________________

UnitedHealth Group Incorporated

(Exact name of registrant as specified in its charter)

__________________________________________________________

Delaware

41-1321939

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

1 Health Drive

55344

655 New York Avenue NW

20001

Eden Prairie,

Minnesota

Washington,

(Address of principal executive offices)

(Zip Code)

(Address of principal executive offices)

(Zip Code)

(800) 328-5979

(Registrant’s telephone number, including area code)

_________________________________________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $.01 par value

UNH

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of April 30, 2025, there were 907,140,441 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.

UNITEDHEALTH GROUP

Table of Contents


			Page

Part I. Financial Information
Item 1.	Financial Statements (unaudited)		1
	Condensed Consolidated Balance Sheets as of March 3 1 , 202 5 and December 31, 202 4		1
	Condensed Consolidated Statements of Operations for the Three Months Ended March 3 1 , 202 5 and 202 4		2
	Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended M arch 3 1 , 202 5 and 202 4		3
	Condensed Consolidated Statements of Changes in Equity for the Three Months Ended Marc h 3 1 , 202 5 and 202 4		4
	Condensed Consolidated Statements of Cash Flows for the Three Months Ended M arch 3 1 , 202 5 and 20 24		5
	Notes to the Condensed Consolidated Financial Statements		6
	1.	Basis of Presentation	6
	2.	Investments	7
	3.	Fair Value	9
	4.	Medical Costs Payable	10
	5 .	Short-Term Borrowings and Long-Term Debt	10
	6 .	Commitments and Contingencies	11
	7 .	Held for Sale	12
	8 .	Segment Financial Information	13
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		14
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		21
Item 4.	Controls and Procedures		22
Part II. Other Information
Item 1.	Legal Proceedings		22
Item 1A.	Risk Factors		22
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		22
Item 5.	Other Information		23
Item 6.	Exhibits		23
Signatures			24

PART I

ITEM 1. FINANCIAL STATEMENTS

UnitedHealth Group

Condensed Consolidated Balance Sheets

(Unaudited)


(in millions, except per share data)	March 31, 2025		December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$	30,717	$	25,312
Short-term investments	3,574		3,801
Accounts receivable, net	26,936		22,365
Other current receivables, net	26,022		26,089
Prepaid expenses and other current assets	9,036		8,212
Total current assets	96,285		85,779
Long-term investments	51,863		52,354
Property, equipment and capitalized software, net	10,734		10,553
Goodwill	107,566		106,734
Other intangible assets, net	22,947		23,268
Other assets	20,395		19,590
Total assets	$	309,790	$	298,278
Liabilities, redeemable noncontrolling interests and equity
Current liabilities:
Medical costs payable	$	37,136	$	34,224
Accounts payable and accrued liabilities	33,566		34,337
Short-term borrowings and current maturities of long-term debt	9,986		4,545
Unearned revenues	3,296		3,317
Other current liabilities	29,487		27,346
Total current liabilities	113,471		103,769
Long-term debt, less current maturities	71,285		72,359
Deferred income taxes	3,902		3,620
Other liabilities	15,963		15,939
Total liabilities	204,621		195,687
Commitments and contingencies (Note 6)
Redeemable noncontrolling interests	4,358		4,323
Equity:
Preferred stock, $ 0.001 par value - 10 shares authorized; no shares issued or outstanding	—		—
Common stock, $ 0.01 par value - 3,000 shares authorized; 910 and 915 issued and outstanding	9		9
Retained earnings	97,934		96,036
Accumulated other comprehensive loss	( 2,905 )		( 3,387 )
Nonredeemable noncontrolling interests	5,773		5,610
Total equity	100,811		98,268
Total liabilities, redeemable noncontrolling interests and equity	$	309,790	$	298,278

See Notes to the Condensed Consolidated Financial Statements

Table of Contents

UnitedHealth Group

Condensed Consolidated Statements of Operations

(Unaudited)


	Three Months Ended March 31,
(in millions, except per share data)	2025		2024
Revenues:
Premiums	$	86,534	$	77,988
Products	13,036		11,909
Services	8,972		8,888
Investment and other income	1,033		1,011
Total revenues	109,575		99,796
Operating costs:
Medical costs	73,411		65,735
Operating costs	13,594		14,077
Cost of products sold	12,390		11,056
Depreciation and amortization	1,061		997
Total operating costs	100,456		91,865
Earnings from operations	9,119		7,931
Interest expense	( 998 )		( 844 )
Loss on sale of subsidiary and subsidiaries held for sale	( 15 )		( 7,086 )
Earnings before income taxes	8,106		1
Provision for income taxes	( 1,632 )		( 1,222 )
Net earnings (loss)	6,474		( 1,221 )
Earnings attributable to noncontrolling interests	( 182 )		( 188 )
Net earnings (loss) attributable to UnitedHealth Group common shareholders	$	6,292	$	( 1,409 )
Earnings (loss) per share attributable to UnitedHealth Group common shareholders:
Basic	$	6.90	$	( 1.53 )
Diluted	$	6.85	$	( 1.53 )
Basic weighted-average number of common shares outstanding	912		922
Dilutive effect of common share equivalents	6		—
Diluted weighted-average number of common shares outstanding	918		922
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents	6		15

See Notes to the Condensed Consolidated Financial Statements

Table of Contents

UnitedHealth Group

Condensed Consolidated Statements of Comprehensive Income

(Unaudited)


	Three Months Ended March 31,
(in millions)	2025		2024
Net earnings (loss)	$	6,474	$	( 1,221 )
Other comprehensive income:
Gross unrealized gains (losses) on investment securities during the period	521		( 290 )
Income tax effect	( 119 )		68
Total unrealized gains (losses), net of tax	402		( 222 )
Gross reclassification adjustment for net realized gains included in net earnings	( 10 )		( 32 )
Income tax effect	2		7
Total reclassification adjustment, net of tax	( 8 )		( 25 )
Foreign currency translation gains (losses)	88		( 293 )
Reclassification adjustment for translation losses included in net earnings (loss)	—		4,128
Total foreign currency translation gains	88		3,835
Other comprehensive income	482		3,588
Comprehensive income	6,956		2,367
Comprehensive income attributable to noncontrolling interests	( 182 )		( 188 )
Comprehensive income attributable to UnitedHealth Group common shareholders	$	6,774	$	2,179

See Notes to the Condensed Consolidated Financial Statements

Table of Contents

UnitedHealth Group

Condensed Consolidated Statements of Changes in Equity

(Unaudited)


	Common Stock			Additional Paid-In Capital		Retained Earnings		Accumulated Other Comprehensive Loss				Nonredeemable Noncontrolling Interests		Total Equity
Three months ended March 31, (in millions)	Shares	Amount						Net Unrealized (Losses) Gains on Investments		Foreign Currency Translation (Losses) Gains
Balance at January 1, 2025	915	$	9	$	—	$	96,036	$	( 2,226 )	$	( 1,161 )	$	5,610	$	98,268
Net earnings						6,292						148		6,440
Other comprehensive income								394		88				482
Issuances of common stock, and related tax effects	1	—		183										183
Share-based compensation				362										362
Common share repurchases	( 6 )	—		( 540 )		( 2,482 )								( 3,022 )
Cash dividends paid on common shares ($ 2.10 per share)						( 1,912 )								( 1,912 )
Redeemable noncontrolling interests fair value and other adjustments				( 5 )										( 5 )
Acquisition and other adjustments of nonredeemable noncontrolling interests												194		194
Distribution to nonredeemable noncontrolling interests												( 179 )		( 179 )
Balance at March 31, 2025	910	9		—		97,934		( 1,832 )		( 1,073 )		5,773		100,811

Balance at January 1, 2024	924	$	9	$	—	$	95,774	$	( 1,971 )	$	( 5,056 )	$	5,665	$	94,421
Net (loss) earnings						( 1,409 )						149		( 1,260 )
Other comprehensive (loss) income								( 247 )		3,835				3,588
Issuances of common stock, and related tax effects	2	—		242										242
Share-based compensation				352										352
Common share repurchases	( 6 )	—		( 574 )		( 2,518 )								( 3,092 )
Cash dividends paid on common shares ($ 1.88 per share)						( 1,729 )								( 1,729 )
Redeemable noncontrolling interests fair value and other adjustments				( 20 )										( 20 )
Acquisition and other adjustments of nonredeemable noncontrolling interests												19		19
Distribution to nonredeemable noncontrolling interests												( 151 )		( 151 )
Balance at March 31, 2024	920	$	9	$	—	$	90,118	$	( 2,218 )	$	( 1,221 )	$	5,682	$	92,370

See Notes to the Condensed Consolidated Financial Statements

Table of Contents

UnitedHealth Group

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Three Months Ended March 31,
(in millions)	2025		2024
Operating activities
Net earnings (loss)	$	6,474	$	( 1,221 )
Noncash items:
Depreciation and amortization	1,061		997
Deferred income taxes	64		( 27 )
Share-based compensation	375		372
Loss on sale of subsidiary and subsidiaries held for sale	15		7,086
Other, net	97		179
Net change in other operating items, net of effects from acquisitions and dispositions:
Accounts receivable	( 4,462 )		( 6,162 )
Other assets	( 544 )		( 1,927 )
Medical costs payable	2,993		2,069
Accounts payable and other liabilities	( 607 )		( 231 )
Unearned revenues	( 10 )		9
Cash flows from operating activities	5,456		1,144
Investing activities
Purchases of investments	( 4,135 )		( 4,798 )
Sales of investments	3,185		2,976
Maturities of investments	2,167		2,314
Cash paid for acquisitions and other transactions, net of cash assumed	( 702 )		( 3,006 )
Purchases of property, equipment and capitalized software	( 898 )		( 743 )
Loans to care providers - cyberattack	—		( 2,164 )
Repayments of care provider loans - cyberattack	891		—
Other, net	( 582 )		( 919 )
Cash flows used for investing activities	( 74 )		( 6,340 )
Financing activities
Common share repurchases	( 3,000 )		( 3,072 )
Cash dividends paid	( 1,912 )		( 1,729 )
Proceeds from common stock issuances	360		486
Repayments of long-term debt	—		( 750 )
Proceeds from short-term borrowings, net	3,911		6,189
Proceeds from issuance of long-term debt	—		5,925
Customer funds administered	1,245		1,745
Other, net	( 505 )		( 563 )
Cash flows from financing activities	99		8,231
Effect of exchange rate changes on cash and cash equivalents	15		( 48 )
Increase in cash and cash equivalents, including cash within businesses held for sale	5,496		2,987
Less: net increase in cash within businesses held for sale	( 91 )		—
Net increase in cash and cash equivalents	5,405		2,987
Cash and cash equivalents, beginning of period	25,312		25,427
Cash and cash equivalents, end of period	$	30,717	$	28,414

See Notes to the Condensed Consolidated Financial Statements

Table of Contents

UnitedHealth Group

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

1. Basis of Presentation

UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. The Company’s two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve.

The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC (2024 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.

Use of Estimates

These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.

Revenues - Products and Services

As of March 31, 2025 and December 31, 2024, accounts receivable related to products and services were $ 11.7 billion and $ 9.9 billion, respectively. As of March 31, 2025, revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was $ 12.4 billion, of which approximately half is expected to be recognized in the next three years .

Table of Contents

2. Investments

A summary of debt securities by major security type is as follows:


(in millions)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
March 31, 2025
Debt securities - available-for-sale:
U.S. government and agency obligations	$	4,276	$	1	$	( 212 )	$	4,065
State and municipal obligations	7,110		4		( 367 )		6,747
Corporate obligations	24,097		65		( 924 )		23,238
U.S. agency mortgage-backed securities	10,410		5		( 812 )		9,603
Non-U.S. agency mortgage-backed securities	2,939		3		( 148 )		2,794
Total debt securities - available-for-sale	48,832		78		( 2,463 )		46,447
Debt securities - held-to-maturity:
U.S. government and agency obligations	447		1		( 1 )		447
State and municipal obligations	27		—		( 3 )		24
Corporate obligations	18		—		—		18
Total debt securities - held-to-maturity	492		1		( 4 )		489
Total debt securities	$	49,324	$	79	$	( 2,467 )	$	46,936
December 31, 2024
Debt securities - available-for-sale:
U.S. government and agency obligations	$	4,600	$	1	$	( 274 )	$	4,327
State and municipal obligations	7,357		2		( 375 )		6,984
Corporate obligations	24,391		56		( 1,140 )		23,307
U.S. agency mortgage-backed securities	10,577		1		( 994 )		9,584
Non-U.S. agency mortgage-backed securities	2,890		2		( 175 )		2,717
Total debt securities - available-for-sale	49,815		62		( 2,958 )		46,919
Debt securities - held-to-maturity:
U.S. government and agency obligations	444		—		( 2 )		442
State and municipal obligations	28		—		( 2 )		26
Corporate obligations	40		—		—		40
Total debt securities - held-to-maturity	512		—		( 4 )		508
Total debt securities	$	50,327	$	62	$	( 2,962 )	$	47,427

The Company held $ 5.1 billion and $ 4.9 billion of equity securities as of March 31, 2025 and December 31, 2024, respectively. The Company’s investments in equity securities primarily consist of venture investments and employee savings plan related investments. Additionally, the Company’s investments included $ 3.4 billion and $ 3.8 billion of equity method investments primarily in operating businesses in the health care sector as of March 31, 2025 and December 31, 2024, respectively. The allowance for credit losses on held-to-maturity securities at March 31, 2025 and December 31, 2024 was not material.

Table of Contents

The amortized cost and fair value of debt securities as of March 31, 2025, by contractual maturity, were as follows:


	Available-for-Sale				Held-to-Maturity
(in millions)	Amortized Cost		Fair Value		Amortized Cost		Fair Value
Due in one year or less	$	3,693	$	3,670	$	341	$	341
Due after one year through five years	14,251		13,885		120		121
Due after five years through ten years	12,248		11,536		14		13
Due after ten years	5,291		4,959		17		14
U.S. agency mortgage-backed securities	10,410		9,603		—		—
Non-U.S. agency mortgage-backed securities	2,939		2,794		—		—
Total debt securities	$	48,832	$	46,447	$	492	$	489

The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:


	Less Than 12 Months				12 Months or Greater				Total
(in millions)	Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses
March 31, 2025
Debt securities - available-for-sale:
U.S. government and agency obligations	$	1,540	$	( 28 )	$	1,944	$	( 184 )	$	3,484	$	( 212 )
State and municipal obligations	2,111		( 67 )		4,150		( 300 )		6,261		( 367 )
Corporate obligations	6,855		( 146 )		10,705		( 778 )		17,560		( 924 )
U.S. agency mortgage-backed securities	4,032		( 114 )		4,660		( 698 )		8,692		( 812 )
Non-U.S. agency mortgage-backed securities	557		( 4 )		1,745		( 144 )		2,302		( 148 )
Total debt securities - available-for-sale	$	15,095	$	( 359 )	$	23,204	$	( 2,104 )	$	38,299	$	( 2,463 )
December 31, 2024
Debt securities - available-for-sale:
U.S. government and agency obligations	$	1,475	$	( 51 )	$	2,152	$	( 223 )	$	3,627	$	( 274 )
State and municipal obligations	2,593		( 58 )		4,085		( 317 )		6,678		( 375 )
Corporate obligations	7,402		( 213 )		11,449		( 927 )		18,851		( 1,140 )
U.S. agency mortgage-backed securities	4,791		( 191 )		4,674		( 803 )		9,465		( 994 )
Non-U.S. agency mortgage-backed securities	416		( 5 )		1,863		( 170 )		2,279		( 175 )
Total debt securities - available-for-sale	$	16,677	$	( 518 )	$	24,223	$	( 2,440 )	$	40,900	$	( 2,958 )

The Company’s unrealized losses from debt securities as of March 31, 2025 were generated from approximately 32,000 positions out of a total of 42,000 positions. The Company believes that it will timely collect the principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company’s assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of March 31, 2025, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities at March 31, 2025 and December 31, 2024 was not material.

Table of Contents

3. Fair Value

Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP.

For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2024 10-K.

The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:


(in millions)	Quoted Prices in Active Markets (Level 1)			Other Observable Inputs (Level 2)			Unobservable Inputs (Level 3)			Total Fair and Carrying Value
March 31, 2025
Cash and cash equivalents	$	30,183		$	534		$	—		$	30,717
Debt securities - available-for-sale:
U.S. government and agency obligations	3,936			129			—			4,065
State and municipal obligations	—			6,747			—			6,747
Corporate obligations	30			22,730			478			23,238
U.S. agency mortgage-backed securities	—			9,603			—			9,603
Non-U.S. agency mortgage-backed securities	—			2,794			—			2,794
Total debt securities - available-for-sale	3,966			42,003			478			46,447
Equity securities	1,708			213			215			2,136
Total assets at fair value	$	35,857		$	42,750		$	693		$	79,300
Percentage of total assets at fair value	45		%	54		%	1		%	100		%
December 31, 2024
Cash and cash equivalents	$	25,248		$	64		$	—		$	25,312
Debt securities - available-for-sale:
U.S. government and agency obligations	4,194			133			—			4,327
State and municipal obligations	—			6,984			—			6,984
Corporate obligations	29			22,841			437			23,307
U.S. agency mortgage-backed securities	—			9,584			—			9,584
Non-U.S. agency mortgage-backed securities	—			2,717			—			2,717
Total debt securities - available-for-sale	4,223			42,259			437			46,919
Equity securities	1,859			24			65			1,948
Total assets at fair value	$	31,330		$	42,347		$	502		$	74,179
Percentage of total assets at fair value	42		%	57		%	1		%	100		%

There were no transfers in or out of Level 3 financial assets or liabilities during the three months ended March 31, 2025 or 2024.

Table of Contents

The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:


(in millions)	Quoted Prices in Active Markets (Level 1)		Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)		Total Fair Value		Total Carrying Value
March 31, 2025
Debt securities - held-to-maturity	$	464	$	25	$	—	$	489	$	492
Long-term debt and other financing obligations	$	—	$	71,337	$	—	$	71,337	$	76,036
December 31, 2024
Debt securities - held-to-maturity	$	482	$	26	$	—	$	508	$	512
Long-term debt and other financing obligations	$	—	$	70,565	$	—	$	70,565	$	75,604

Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. The assets and liabilities within our South American operations held for sale as of March 31, 2025 were measured at the lower of carrying value or fair value less cost to sell. Fair value is measured based upon unobservable amounts, such as estimated selling price derived from Company-specific information and market conditions. There were no significant fair value adjustments for assets and liabilities recorded during the three months ended March 31, 2025 or 2024.

4. Medical Costs Payable

The following table shows the components of the change in medical costs payable for the three months ended March 31:


(in millions)	2025		2024
Medical costs payable, beginning of period	$	34,224	$	32,395
Acquisitions (dispositions), net	—		( 687 )
Reported medical costs:
Current year	73,731		66,045
Prior years	( 320 )		( 310 )
Total reported medical costs	73,411		65,735
Medical payments:
Payments for current year	( 43,827 )		( 38,652 )
Payments for prior years	( 26,669 )		( 24,759 )
Total medical payments	( 70,496 )		( 63,411 )
Less: increase in medical costs payable included within businesses held for sale	( 3 )		—
Medical costs payable, end of period	$	37,136	$	34,032

For the three months ended March 31, 2025 and 2024, prior years’ medical cost reserve development included no individual factors that were significant. Medical costs payable included reserves for claims incurred by consumers but not yet reported to the Company of $ 25.9 billion and $ 23.7 billion at March 31, 2025 and December 31, 2024, respectively.

5. Short-Term Borrowings and Long-Term Debt

As of March 31, 2025, the Company had $ 5.2 billion of commercial paper outstanding, with a weighted-average annual interest rate of 4.4 %.

For more information on the Company’s short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2024 10-K.

Table of Contents

6. Commitments and Contingencies

Pending Acquisitions

As of March 31, 2025, the Company had entered into agreements to acquire companies in the health care sector, subject to regulatory approval and other customary closing conditions. The total anticipated capital required for these acquisitions, excluding the payoff of acquired indebtedness, was approximately $ 4 billion.

Legal Matters

The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices.

The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be incurred.

Government Investigations, Audits and Reviews

The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office for Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Consumer Financial Protection Bureau, the Defense Contract Audit Agency, the Food and Drug Administration and other governmental authorities. Similarly, the Company’s international businesses are also subject to investigations, audits and reviews by applicable foreign governments. The Company has also been responding to subpoenas, information requests and investigations from governmental entities. The Company can provide no assurance as to the scope and outcome of these matters and no assurance as to whether its business, financial condition or results of operations will be materially adversely affected. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans.

On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. In March 2025, a Special Master appointed by the court issued a report recommending that the court enter summary judgment in the Company’s favor on all remaining claims. In April 2025, the DOJ filed a motion asking the court to reject the Special Master’s report. The Company cannot reasonably estimate the outcome which may result from this matter given its procedural status.

Table of Contents

7. Held for Sale

The Company’s planned sales of its remaining South American operations are expected to close within the year, subject to regulatory and other customary closing conditions. Assets and liabilities held for sale have been included within prepaid expenses and other current assets and other current liabilities on the Condensed Consolidated Balance Sheet, respectively.

The assets and liabilities of the held for sale disposal groups as of March 31, 2025, were as follows:


(in millions)	Businesses Held for Sale
Assets
Cash and cash equivalents	$	310
Accounts receivable and other current assets	637
Property, equipment and capitalized software	690
Goodwill and other intangible assets	440
Other long-term assets	287
Remeasurement of assets of businesses held for sale to fair value less cost to sell (1)	( 1,272 )
Total assets	$	1,092
Liabilities
Medical costs payable	$	182
Accounts payable and other current liabilities	459
Other long-term liabilities	411
Total liabilities	$	1,052

(1) Includes the effect of $ 849 million of cumulative foreign currency translation losses and $ 50 million of noncontrolling interests.

Table of Contents

8. Segment Financial Information

The Company’s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more information on the Company’s segments, see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2024 10-K.

The following tables present reportable segment financial information:


			Optum
(in millions)	UnitedHealthcare		Optum Health		Optum Insight		Optum Rx		Optum Eliminations		Optum		Corporate and Eliminations		Consolidated
Three Months Ended March 31, 2025
Revenues - unaffiliated customers:
Premiums	$	81,513	$	5,021	$	—	$	—	$	—	$	5,021	$	—	$	86,534
Products	—		65		44		12,927		—		13,036		—		13,036
Services	2,576		3,874		1,501		1,021		—		6,396		—		8,972
Total revenues - unaffiliated customers	84,089		8,960		1,545		13,948		—		24,453		—		108,542
Total revenues - affiliated customers	—		15,914		3,062		21,137		( 1,186 )		38,927		( 38,927 )		—
Investment and other income	528		435		23		47		—		505		—		1,033
Total revenues	$	84,617	$	25,309	$	4,630	$	35,132	$	( 1,186 )	$	63,885	$	( 38,927 )	$	109,575
Total operating costs (a)	$	79,391	$	23,695	$	3,669	$	33,814	$	( 1,186 )	$	59,992	$	( 38,927 )	$	100,456
Earnings from operations	$	5,226	$	1,614	$	961	$	1,318	$	—	$	3,893	$	—	$	9,119
Interest expense	—		—		—		—		—		—		( 998 )		( 998 )
Loss on sale of subsidiary and subsidiaries held for sale	( 15 )		—		—		—		—		—		—		( 15 )
Earnings before income taxes	$	5,211	$	1,614	$	961	$	1,318	$	—	$	3,893	$	( 998 )	$	8,106
Total assets	$	131,902	$	97,722	$	34,470	$	60,379	$	—	$	192,571	$	( 14,683 )	$	309,790
Purchases of property, equipment and capitalized software	196		279		338		85		—		702		—		898
Depreciation and Amortization	219		287		344		211		—		842		—		1,061
Three Months Ended March 31, 2024
Revenues - unaffiliated customers:
Premiums	$	72,293	$	5,695	$	—	$	—	$	—	$	5,695	$	—	$	77,988
Products	—		59		41		11,809		—		11,909		—		11,909
Services	2,529		3,970		1,702		687		—		6,359		—		8,888
Total revenues - unaffiliated customers	74,822		9,724		1,743		12,496		—		23,963		—		98,785
Total revenues - affiliated customers	—		16,617		2,731		18,281		( 1,016 )		36,613		( 36,613 )		—
Investment and other income	535		390		28		58		—		476		—		1,011
Total revenues	$	75,357	$	26,731	$	4,502	$	30,835	$	( 1,016 )	$	61,052	$	( 36,613 )	$	99,796
Total operating costs (a)	$	70,962	$	24,832	$	4,012	$	29,688	$	( 1,016 )	$	57,516	$	( 36,613 )	$	91,865
Earnings from operations	$	4,395	$	1,899	$	490	$	1,147	$	—	$	3,536	$	—	$	7,931
Interest expense	—		—		—		—		—		—		( 844 )		( 844 )
Loss on sale of subsidiary and subsidiaries held for sale	( 7,086 )		—		—		—		—		—		—		( 7,086 )
Earnings before income taxes	$	( 2,691 )	$	1,899	$	490	$	1,147	$	—	$	3,536	$	( 844 )	$	1
Total assets	$	112,840	$	94,861	$	34,220	$	55,291	$	—	$	184,372	$	( 13,002 )	$	284,210
Purchases of property, equipment and capitalized software	183		238		245		77		—		560		—		743
Depreciation and Amortization	235		272		310		180		—		762		—		997

(a) Total operating costs include medical costs, operating costs, cost of products sold and depreciation and amortization, as applicable for each reportable segment.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and Notes and with our 2024 10-K, including the Consolidated Financial Statements and Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in that report. Unless the context indicates otherwise, references to the terms “UnitedHealth Group,” the “Company,” “we,” “our” or “us” used throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.

Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2024 10-K and in the discussion below.

EXECUTIVE OVERVIEW

General

UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations we are privileged to serve.

We have four reportable segments:

• Optum Health;

• Optum Insight;

• Optum Rx; and

• UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State.

Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2024 10-K and additional information on our segments can be found in this Item 2 and in Note 8 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

Business Trends

Our businesses participate primarily in the United States health markets. We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being. The rate of market growth may be affected by a variety of factors, including macroeconomic conditions and regulatory changes, which could impact our results of operations, including our continued efforts to control health care costs.

Pricing Trends. To price our health care benefits, products and services, we start with our view of expected future costs, including medical care patterns, the mix and health status of people served, inflation and labor market dynamics. We frequently evaluate and adjust our approach in each of the local markets we serve, considering relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations, including minimum medical loss ratio thresholds and similar revenue adjustments. We will continue seeking to balance growth and profitability across all these dimensions.

The commercial risk market remains highly competitive in the small group, large group and individual segments. We expect broad-based competition to continue as the industry adapts to individual and employer needs.

Medicare Advantage funding continues to be pressured, as discussed below in “ R egulatory Trends and Uncertainties” and we have observed increased care patterns as discussed below in “Medical Cost Trends,” which may impact pricing and benefit design in future periods.

Table of Contents

The Medicaid redetermination process has caused a timing mismatch between the health status of people served through Medicaid and state rate updates. While the updated rates in 2025 more closely align with underlying member acuity, the funding and payment rate environment remains insufficient to meet the health needs of patients and creates the risk of continued downward pressure on Medicaid margin percentages. We continue to take a prudent, market-sustainable posture for both new business and maintenance of existing relationships. We continue to advocate for actuarially sound rates commensurate with our medical cost trends and we remain dedicated to partnering with those states that are committed to the long-term viability of their programs.

Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, care activity and prescription drug costs. We have observed increased care patterns, more notably related to physician and outpatient care for seniors served through Medicare Advantage, that are above what we expected and contemplated in our benefits design. These elevated care patterns may continue in future periods. Additionally, the Inflation Reduction Act (IRA) altered the Medicare Part D model and benefits, shifting more risk to plans, which results in both increased premiums and medical costs. The IRA also changed the quarterly relationship of medical costs to premiums, altering the seasonal progression and creating a more consistent relationship between medical costs and premiums throughout the year. We endeavor to mitigate medical cost increases by engaging hospitals, physicians and consumers with information and helping them make clinically sound choices, with the objective of helping them achieve high-quality, affordable care.

Regulatory Trends and Uncertainties

Medicare Advantage Rates. Medicare Advantage rate notices for numerous years have resulted in industry base rates well below the industry forward medical cost trend, with the Final Notice for 2026 beginning to approach the industry forward medical cost trend. The compounding impact of the previous multi-year rate shortfalls creates sustained pressure on the Medicare Advantage program. Further, substantial revisions to the risk adjustment model, which serves to adjust rates to reflect a patient’s health status and care resource needs, have and will result in reduced funding and potentially benefits for people, especially those with some of the greatest health and social challenges.

As a result of ongoing Medicare funding pressures, there are adjustments we can make to partially offset these rate pressures and reductions for a particular period. For example, we can seek to intensify our medical and operating cost management, make changes to the size and composition of our care provider networks, adjust member benefits and implement or increase the member premiums supplementing the monthly payments we receive from the government. Additionally, we decide annually on a county-by-county basis where we will offer Medicare Advantage plans.

SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS

The following summarizes select first quarter 2025 year-over-year operating comparisons to first quarter 2024 and other financial results.

• Consolidated revenues grew 10%, UnitedHealthcare revenues grew 12% and Optum revenues grew 5%.

• UnitedHealthcare served 945,000 more people, driven by growth in commercial offerings and Medicare Advantage.

• Consolidated earnings from operations of $9.1 billion compared to $7.9 billion last year, with 2024 impacted by the Change Healthcare cyberattack.

• Diluted earnings per common share was $6.85.

• Cash flows from operations for the three months ended March 31, 2025 were $5.5 billion.

Table of Contents

RESULTS SUMMARY

The following table summarizes our consolidated results of operations and other financial information:


(in millions, except percentages and per share data)	Three Months Ended March 31,						Increase/ (Decrease)
	2025			2024			2025 vs. 2024
Revenues:
Premiums	$	86,534		$	77,988		$	8,546		11	%
Products	13,036			11,909			1,127			9
Services	8,972			8,888			84			1
Investment and other income	1,033			1,011			22			2
Total revenues	109,575			99,796			9,779			10
Operating costs:
Medical costs	73,411			65,735			7,676			12
Operating costs	13,594			14,077			(483)			(3)
Cost of products sold	12,390			11,056			1,334			12
Depreciation and amortization	1,061			997			64			6
Total operating costs	100,456			91,865			8,591			9
Earnings from operations	9,119			7,931			1,188			15
Interest expense	(998)			(844)			(154)			18
Loss on sale of subsidiary and subsidiaries held for sale	(15)			(7,086)			7,071			nm
Earnings before income taxes	8,106			1			8,105			nm
Provision for income taxes	(1,632)			(1,222)			(410)			34
Net earnings (loss)	6,474			(1,221)			7,695			nm
Earnings attributable to noncontrolling interests	(182)			(188)			6			(3)
Net earnings (loss) attributable to UnitedHealth Group common shareholders	$	6,292		$	(1,409)		$	7,701		nm
Diluted earnings (loss) per share attributable to UnitedHealth Group common shareholders	$	6.85		$	(1.53)		$	8.38
Medical care ratio (a)	84.8		%	84.3		%	0.5		%
Operating cost ratio	12.4			14.1			(1.7)
Operating margin	8.3			7.9			0.4
Tax rate	20.1			nm			nm
Net earnings margin (b)	5.7			(1.4)			7.1
Return on equity (c)	26.8		%	nm			nm

nm = not meaningful

(a) Medical care ratio (MCR) is calculated as medical costs divided by premium revenue.

(b) Net earnings margin attributable to UnitedHealth Group shareholders.

(c) Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’ equity. Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year and the shareholders’ equity balances at the end of each of the quarters in the year presented.

2025 RESULTS OF OPERATIONS COMPARED TO 2024 RESULTS OF OPERATIONS

Consolidated Financial Results

Revenues

The increases in revenues were primarily driven by growth across our UnitedHealthcare domestic offerings and Optum Rx and pricing trends.

Medical Costs and MCR

Medical costs increased primarily due to growth in people served through Medicare Advantage, domestic commercial offerings and those with higher acuity needs; the IRA-driven impacts on Medicare Part D plans and elevated care patterns. The MCR increased as a result of the revenue effects of the Medicare funding reductions, the member profile of newly added patients under value-based care arrangements and elevated care patterns for seniors served through Medicare Advantage, partially offset by the seasonal impacts of the IRA on Medicare Part D and the incremental medical costs for accommodations made to care providers as a results of the Change Healthcare cyberattack incurred in 2024.

Table of Contents

Operating Cost Ratio

The operating cost ratio decreased primarily due to operating cost management; revenue impacts of government programs, including the IRA-driven impacts on Medicare Part D plans; and our direct response efforts to the Change Healthcare cyberattack incurred in 2024, partially offset by investments to support future growth.

Reportable Segments

See Note 8 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more information on our segments. We utilize various metrics to evaluate and manage our reportable segments, including people served by UnitedHealthcare by major market segment and funding arrangement, people served by Optum Health and adjusted scripts for Optum Rx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also allow management and investors to evaluate and understand business mix, including the level and scope of services provided to people, and pricing trends when comparing the metrics to revenue by segment.

The following table presents a summary of the reportable segment financial information:


	Three Months Ended March 31,						Increase/ (Decrease)
(in millions, except percentages)	2025			2024			2025 vs. 2024
Revenues
UnitedHealthcare	$	84,617		$	75,357		$	9,260		12	%
Optum Health	25,309			26,731			(1,422)			(5)
Optum Insight	4,630			4,502			128			3
Optum Rx	35,132			30,835			4,297			14
Optum eliminations	(1,186)			(1,016)			(170)			17
Optum	63,885			61,052			2,833			5
Eliminations	(38,927)			(36,613)			(2,314)			6
Consolidated revenues	$	109,575		$	99,796		$	9,779		10	%
Earnings from operations
UnitedHealthcare	$	5,226		$	4,395		$	831		19	%
Optum Health	1,614			1,899			(285)			(15)
Optum Insight	961			490			471			96
Optum Rx	1,318			1,147			171			15
Optum	3,893			3,536			357			10
Consolidated earnings from operations	$	9,119		$	7,931		$	1,188		15	%
Operating margin
UnitedHealthcare	6.2		%	5.8		%	0.4		%
Optum Health	6.4			7.1			(0.7)
Optum Insight	20.8			10.9			9.9
Optum Rx	3.8			3.7			0.1
Optum	6.1			5.8			0.3
Consolidated operating margin	8.3		%	7.9		%	0.4		%

UnitedHealthcare

The following table summarizes UnitedHealthcare revenues by business:


	Three Months Ended March 31,				Increase/ (Decrease)
(in millions, except percentages)	2025		2024		2025 vs. 2024
UnitedHealthcare Employer & Individual - Domestic	$	19,066	$	17,839	$	1,227	7	%
UnitedHealthcare Employer & Individual - Global	782		1,532		(750)		(49)
UnitedHealthcare Employer & Individual - Total	19,848		19,371		477		2
UnitedHealthcare Medicare & Retirement	41,705		35,486		6,219		18
UnitedHealthcare Community & State	23,064		20,500		2,564		13
Total UnitedHealthcare revenues	$	84,617	$	75,357	$	9,260	12	%

Table of Contents

The following table summarizes the number of people served by our UnitedHealthcare businesses, by major market segment and funding arrangement:


	March 31,		Increase/(Decrease)
(in thousands, except percentages)	2025	2024	2025 vs. 2024
Commercial:
Risk-based	8,410	8,545	(135)	(2)	%
Fee-based	21,590	20,870	720	3
Total Commercial	30,000	29,415	585	2
Medicare Advantage	8,245	7,760	485	6
Medicaid	7,570	7,680	(110)	(1)
Medicare Supplement (Standardized)	4,310	4,325	(15)	—
Total Community and Senior	20,125	19,765	360	2
Total UnitedHealthcare - Medical	50,125	49,180	945	2
Supplemental Data:
Medicare Part D stand-alone	2,835	3,085	(250)	(8)	%
South American businesses held for sale	1,160	2,295	(1,135)	(49)	%

UnitedHealthcare’s revenues increased due to growth in the number of people served through Medicare Advantage, fee-based commercial offerings and those with higher acuity needs and the IRA-driven impacts on Medicare Part D plans, partially offset by decreased people served through risk-based commercial offerings and Medicaid redeterminations throughout 2024. Earnings from operations increased primarily due to growth in people served in Medicare Advantage, the seasonal impact of the IRA on Medicare Part D and the incremental medical costs for accommodations to support care providers as a result of the Change Healthcare cyberattack incurred in 2024, partially offset by the impacts of Medicare Advantage funding reductions and elevated care patterns for seniors served through Medicare Advantage.

Optum

Total revenues increased primarily due to growth at Optum Rx, partially offset by Optum Health. Earnings from operations increased due to the impacts of the Change Healthcare cyberattack incurred in 2024 and growth at Optum Rx. The results by segment were as follows:

Optum Health

Revenues at Optum Health decreased primarily due to the conversion of risk-based contracts, Medicare Advantage funding reductions and the profile of members served, partially offset by growth in patients served under value-based arrangements. Earnings from operations decreased due to Medicare Advantage funding reductions, the member profile of newly added patients under value-based care arrangements and elevated care patterns for seniors served through Medicare Advantage, partially offset by cost management initiatives and the incremental medical costs for accommodations to support care providers as a result of the Change Cyberattack incurred in 2024. Optum Health served approximately 99 million people and 104 million people as of March 31, 2025 and March 31, 2024, respectively.

Optum Insight

Revenues at Optum Insight increased due to decreased business disruption impacts related to the Change Healthcare cyberattack. Earnings from operations at Optum Insight increased due to decreased business disruption impacts and direct response costs related to the Change Healthcare cyberattack.

Optum Rx

Revenues and earnings from operations at Optum Rx increased due to higher script volumes from both new clients and growth in existing clients and growth in pharmacy services. Earnings from operations also increased due to operating cost efficiencies. Optum Rx fulfilled 408 million and 395 million adjusted scripts in the first quarters of 2025 and 2024, respectively.

Table of Contents

LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES

Liquidity

Summary of our Major Sources and Uses of Cash and Cash Equivalents


	Three Months Ended March 31,				Increase/(Decrease)
(in millions)	2025		2024		2025 vs. 2024
Sources of cash:
Cash provided by operating activities	$	5,456	$	1,144	$	4,312
Issuances of short-term borrowings and long-term debt, net of repayments	3,911		11,364		(7,453)
Proceeds from common stock issuances	360		486		(126)
Customer funds administered	1,245		1,745		(500)
Sales and maturities of investments, net of purchases	1,217		492		725
Repayments of care provider loans - cyberattack	891		—		891
Total sources of cash	13,080		15,231		(2,151)
Uses of cash:
Common stock repurchases	(3,000)		(3,072)		72
Cash paid for acquisitions and other transactions, net of cash assumed	(702)		(3,006)		2,304
Purchases of property, equipment and capitalized software	(898)		(743)		(155)
Cash dividends paid	(1,912)		(1,729)		(183)
Loans to care providers - cyberattack	—		(2,164)		2,164
Other	(1,087)		(1,482)		395
Total uses of cash	(7,599)		(12,196)		4,597
Effect of exchange rate changes on cash and cash equivalents	15		(48)		63
Increase in cash and cash equivalents, including cash within businesses held for sale	$	5,496	$	2,987	$	2,509
Less: net increase in cash within businesses held for sale	(91)		—		(91)
Net increase in cash and cash equivalents	$	5,405	$	2,987	$	2,418

2025 Cash Flows Compared to 2024 Cash Flows

Increased cash flows provided by operating activities were driven by changes in working capital accounts, the seasonal impact of the IRA on Medicare Part D and the impacts of the Change Healthcare cyberattack incurred in 2024. Other significant changes in sources or uses of cash year-over-year included net repayments of loans to care providers in response to the Change Healthcare cyberattack, decreased cash paid for acquisitions and increased net sales and maturities of investments, offset by decreased net issuances of short-term borrowings and long-term debt and decreased customer funds administered.

Financial Condition

As of March 31, 2025, our cash, cash equivalent, available-for-sale debt securities and marketable equity securities balances of $79.1 billion included approximately $30.7 billion of cash and cash equivalents (of which $1.5 billion was available for general corporate use), $46.4 billion of debt securities and $1.9 billion of investments in marketable equity securities. Given the significant portion of our portfolio held in cash and cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a material impact on our liquidity or capital position. Our available-for-sale debt securities portfolio had a weighted-average duration of 4.2 years and a weighted-average credit rating of “Double A” as of March 31, 2025. When multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average credit rating.

Capital Resources and Uses of Liquidity

In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital resources and uses of liquidity are as follows:

Cash Requirements. A summary of our cash requirements as of December 31, 2024 was disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2024 10-K. During the three months ended March 31, 2025, there were no material changes to this previously disclosed information outside the ordinary course of business. We believe our capital resources are sufficient to meet future, short-term and long-term, liquidity needs. We continually evaluate opportunities to expand our operations, including through internal development of new products, programs and technology applications and business combinations.

Table of Contents

Short-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing program, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 5 of the Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2024 10-K.

As of March 31, 2025, we were in compliance with the various covenants under our bank credit facilities.

Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, such as to meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information on our long-term debt, see Note 5 of the Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2024 10-K.

Credit Ratings. Our credit ratings as of March 31, 2025 were as follows:

Moody’s

S&P Global

Fitch

A.M. Best

Ratings

Outlook

Ratings

Outlook

Ratings

Outlook

Ratings

Outlook

Senior unsecured debt

Stable

A+

Stable

Commercial paper

P-1

n/a

A-1

n/a

AMB-1+

n/a

The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase the cost of borrowing for us or limit our access to capital.

Share Repurchase Program. During the three months ended March 31, 2025, we repurchased approximately 6.0 million shares at an average price of $503.72 per share. As of March 31, 2025, we had Board of Directors’ authorization to purchase up to 27 million shares of our common stock. The Board of Directors from time to time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the program.

Dividends. Our quarterly cash dividend to shareholders reflects an annual rate of $8.40.

Pending Acquisitions. As of March 31, 2025, we have entered into agreements to acquire companies in the health care sector, subject to regulatory approval and other customary closing conditions. The total anticipated consideration required for these acquisitions, excluding the payoff of acquired indebtedness, was approximately $4 billion.

For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II, Item 7 in our 2024 10-K.

RECENTLY ISSUED ACCOUNTING STANDARDS

There are no recently issued accounting standards that are expected to have a material impact on our Condensed Consolidated Financial Statements.

CRITICAL ACCOUNTING ESTIMATES

In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates, which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends. On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results, however, may materially differ from our calculated estimates, and this difference would be reported in our current operations.

Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II, Item 7 in our 2024 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2024 10-K.

Table of Contents

FORWARD-LOOKING STATEMENTS

The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities laws. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify forward-looking statements. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or application; cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; the DOJ’s legal action relating to the risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; risks and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to our public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of potential changes in tax laws and regulations; increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to complete, manage or integrate strategic transactions; risk and uncertainties associated with the sale of our remaining operations in South America; risks associated with public health crises arising from large-scale medical emergencies, pandemics, natural disasters and other extreme events; failure to attract, develop, retain, and manage the succession of key employees and executives; our investment portfolio performance; impairment of our goodwill and intangible assets; failure to protect proprietary rights to our databases, software and related products; downgrades in our credit ratings; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, reinvest in our business, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock.

This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial condition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements, except as required by law.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in comprehensive income.

The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of March 31, 2025 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages):


	March 31, 2025
Increase (Decrease) in Market Interest Rate	Investment Income Per Annum		Interest Expense Per Annum		Fair Value of Financial Assets		Fair Value of Financial Liabilities
2 %	$	777	$	645	$	(4,142)	$	(8,978)
1	389		322		(2,117)		(4,896)
(1)	(389)		(305)		2,169		5,927
(2)	(777)		(610)		4,350		13,169

Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2025. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2025.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

A description of our legal proceedings is included in and incorporated by reference to Note 6 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” of our 2024 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2024 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.

There have been no material changes to the risk factors as disclosed in our 2024 10-K.

ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities (a)

First Quarter 2025


For the Month Ended	Total Number of Shares Purchased	Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares That May Yet Be Purchased Under The Plans or Programs
	(in millions)			(in millions)	(in millions)
January 31, 2025	2.2	$	525.07	2.2	30.9
February 28, 2025	2.9	493.53		2.9	28.0
March 31, 2025	0.9	483.99		0.9	27.1
Total	6.0	$	503.72	6.0

(a) In November 1997, our Board of Directors adopted a share repurchase program, which the Board of Directors evaluates periodically. In June 2024, the Board of Directors amended our share repurchase program to authorize the repurchase of up to 35 million shares of our common stock in open market purchases or other types of transactions (including prepaid or structured repurchase programs), in addition to all remaining shares authorized to be repurchased under the Board’s 2018 renewal of the program. There is no established expiration date for the program. The Board of Directors from time to time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the program.

Table of Contents

ITEM 5. OTHER INFORMATION

Trading Arrangements

During the quarter ended March 31, 2025, none of the Company’s directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule 10b5-1 trading arrangement.

ITEM 6. EXHIBITS*

The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the Securities Exchange Act of 1934 under Commission File No. 1-10864.


3.1						Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form 8-A/A filed on July 1, 2015)
3.2						Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated by reference to Exhibit 3.2 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on February 26, 2021)
4.1						Amended and Restated Indenture, dated as of April 27, 2023, between UnitedHealth Group Incorporated and Wilmington Trust Company, as successor trustee (incorporated by reference to Exhibit 4.1 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on April 28, 2023)
4.2						Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-3, SEC File Number 333-149031, filed on February 4, 2008)
4.3						Supplemental Indenture, dated as of April 18, 2023, between UnitedHealth Group Incorporated and U.S. Bank Trust Company, National Association, as trustee, relating to the 6.875% Senior Notes due 2038 (incorporated by reference to Exhibit 4.1 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on April 24, 2023)
31.1						Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1						Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS						XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH						Inline XBRL Taxonomy Extension Schema Document.
101.CAL						Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF						Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB						Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE						Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104						Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).

________________


*						Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

UNITEDHEALTH GROUP INCORPORATED

/s/ A NDREW W ITTY

Chief Executive Officer
(principal executive officer)

Dated:

May 6, 2025

Andrew Witty

/s/ J OHN R EX

President and Chief Financial Officer
(principal financial officer)

Dated:

May 6, 2025

John Rex

/s/ T HOMAS R OOS

Senior Vice President and
Chief Accounting Officer
(principal accounting officer)

Dated:

May 6, 2025

Thomas Roos

TABLE OF CONTENTS

Part Iprint Item 1. Financial Statementsprint Item 2. Management S Discussion and Analysis Of Financial Condition and Results Of Operationsprint Item 3. Quantitative and Qualitative Disclosures About Market Riskprint Item 4. Controls and Proceduresprint Part II. Other Informationprint Item 1. Legal Proceedingsprint Item 1A. Risk Factorsprint Item 2. Unregistered Sale Of Equity Securities and Use Of Proceedsprint Item 5. Other Informationprint Item 6. Exhibits*print

Exhibits

Customer name	Ticker
DaVita Inc.	DVA
The Kroger Co.	KR

Supplier name	Ticker
AbbVie Inc.	ABBV
Abbott Laboratories	ABT
Cognizant Technology Solutions Corporation	CTSH
Johnson & Johnson	JNJ
Gilead Sciences, Inc.	GILD
Eli Lilly and Company	LLY
Pfizer Inc.	PFE

UNH 10-Q Quarter ended March 31, 2025

Exhibits